IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Phone650-940-4700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.60 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable
IRIDEX (NASDAQ:IRIX) Frequently Asked Questions
What is IRIDEX's stock symbol?
IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."
How were IRIDEX's earnings last quarter?
IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Tuesday, March, 5th. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.03. IRIDEX had a negative net margin of 30.08% and a negative return on equity of 45.61%. View IRIDEX's Earnings History.
When is IRIDEX's next earnings date?
What guidance has IRIDEX issued on next quarter's earnings?
IRIDEX updated its FY 2019 earnings guidance on Tuesday, March, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $43-46 million, compared to the consensus revenue estimate of $47.05 million.
What price target have analysts set for IRIX?
2 analysts have issued 1-year price objectives for IRIDEX's shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate IRIDEX's stock price to reach $8.50 in the next year. This suggests a possible upside of 96.8% from the stock's current price. View Analyst Price Targets for IRIDEX.
What is the consensus analysts' recommendation for IRIDEX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.
Has IRIDEX been receiving favorable news coverage?
News headlines about IRIX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IRIDEX earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the near term.
Who are some of IRIDEX's key competitors?
Some companies that are related to IRIDEX include Helius Medical Technologies (HSDT), Zynex (ZYXI), Fonar (FONR), Stereotaxis (STXS), BioSig Technologies (BSGM), Second Sight Medical Products (EYES), Edap Tms (EDAP), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Digirad (DRAD), ENDRA Life Sciences (NDRA), Precision Optics (PEYE), Nexeon Medsystems (NXNN), Non-Invasive Monitoring Systems (NIMU) and Vaso (VASO).
What other stocks do shareholders of IRIDEX own?
Who are IRIDEX's key executives?
IRIDEX's management team includes the folowing people:
- Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
- Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
- Mr. Romeo R. Dizon, VP of Fin.
- Ms. Leigh Salvo, Head of Investor Relations
- Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)
Who are IRIDEX's major shareholders?
IRIDEX's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.52%), Dimensional Fund Advisors LP (1.52%), Isthmus Partners LLC (0.94%), BlackRock Inc. (0.60%), Alambic Investment Management L.P. (0.49%) and Essex Investment Management Co. LLC (0.48%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon and William M Moore. View Institutional Ownership Trends for IRIDEX.
Which institutional investors are selling IRIDEX stock?
IRIX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Osborne Partners Capital Management LLC, FineMark National Bank & Trust and Northern Trust Corp. View Insider Buying and Selling for IRIDEX.
Which institutional investors are buying IRIDEX stock?
IRIX stock was purchased by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Essex Investment Management Co. LLC, BlackRock Inc., Isthmus Partners LLC, Stifel Financial Corp, Quantum Capital Management, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove and William M Moore. View Insider Buying and Selling for IRIDEX.
How do I buy shares of IRIDEX?
Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IRIDEX's stock price today?
One share of IRIX stock can currently be purchased for approximately $4.32.
How big of a company is IRIDEX?
IRIDEX has a market capitalization of $58.71 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.
What is IRIDEX's official website?
How can I contact IRIDEX?
IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]
MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
